TY - T1 - Adenovirus Armed With TNFa and IL2 Added to aPD-1 Regimen Mediates Antitumor Efficacy in Tumors Refractory to aPD-1 SN - / UR - http://hdl.handle.net/10138/334437 T3 - A1 - Cervera-Carrascon, Victor; Quixabeira, Dafne C. A.; Santos, Joao M.; Havunen, Riikka; Milenova, Ioanna; Verhoeff, Jan; Heinio, Camilla; Zafar, Sadia; Garcia-Vallejo, Juan J.; van Beusechem, Victor W.; de Gruijl, Tanja D.; Kalervo, Aino; Sorsa, Suvi; Kanerva, Anna; Hemminki, Akseli A2 - PB - Y1 - 2021 LA - eng AB - Immune checkpoint inhibitors such as anti-PD-1 have revolutionized the field of oncology over the past decade. Nevertheless, the majority of patients do not benefit from them. Virotherapy is a flexible tool that can be used to stimulate and/or recruit different immune populations. T-cell enabling virotherapy could enhance the efficacy of immune checkpoint inhibitors, even in tumors resistant to these inhibitors. The T-cell potentiating virotherapy used here consisted of adenoviruses engineered t... VO - IS - SP - OP - KW - cancer immunotherapy; oncolytic virus; adenovirus; checkpoint inhibitor resistance; tumor microenvironment; IMMUNE CHECKPOINT INHIBITORS; NECROSIS-FACTOR-ALPHA; T-CELL THERAPY; ACQUIRED-RESISTANCE; ONCOLYTIC VIRUSES; PD-1 BLOCKADE; COMBINATION; IMPROVES; LANDSCAPE; 3111 Biomedicine N1 - PP - ER -